Eli Lilly's Trading Volume Drops 50.71% to 15.85 Billion, Ranks 37th as Stock Price Rises 0.49% Amid $1.3 Billion Acquisition of Verve Therapeutics

On June 30, 2025, Eli Lilly's trading volume reached 15.85 billion, marking a 50.71% decrease from the previous day. This placed Eli Lilly at the 37th position in terms of trading volume for the day. Meanwhile, Eli Lilly's stock price increased by 0.49%.

Eli Lilly has announced its acquisition of Verve Therapeutics, a gene-editing specialist, for $1.3 billion. This strategic move is aimed at enhancing Eli Lilly's capabilities in genetic medicine and cardiovascular treatments. The acquisition is part of Eli Lilly's broader strategy to invest heavily in innovative therapies, positioning the company as a leader in the pharmaceutical industry.

Eli Lilly's decision to acquire Verve Therapeutics is seen as a significant step forward in the company's efforts to develop next-generation treatments. The acquisition is expected to bolster Eli Lilly's portfolio of genetic therapies, particularly in the area of cardiovascular health. This move aligns with Eli Lilly's long-term vision of leveraging cutting-edge technology to address unmet medical needs.